CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 55,759 enrolled
Drug / intervention
Parenteral anticoagulant +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05022563
NCT05022563N/ACompleted

Treatment Patterns and Clinical Outcomes Among Venous Thromboembolism Patients Treated With Anticoagulants After the Entry of Non-vitamin K Antagonist Oral Anticoagulants in Korea

Pfizer·observational·Posted Aug 26, 2021·Updated Aug 3, 2023

In Brief

An observational study evaluating Parenteral anticoagulant, Warfarin, and 4 other interventions for Venous Thromboembolism. Completed, enrolled 55,759 participants across 2 sites.

Detailed Summary

This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database. The aims of this study are to describe the sociodemographic and clinical characteristics of patients with venous thromboembolism according to their anticoagulant treatment (parenteral anticoagulants, warfarin, or non-vitamin K antagonist oral anticoagulants), to describe the treatment patterns related to anticoagulants, and to examine the risk of major bleeding according to the specific type of oral anticoagulants. The study will be conducted in two phases: Phase I for descriptive study and Phase II for comparative study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 26, 2021
Enrollment StartAug 31, 2021
Primary CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 29 daysPosted 4.9 years ago

Interventions

Parenteral anticoagulantdrug

Parenteral anticoagulant only

Warfarindrug

Warfarin-based

Apixabandrug

Apixaban

Rivaroxabandrug

Rivaroxaban

Dabigatrandrug

Dabigatran

Edoxabandrug

Edoxaban